Process in the mechanisms of endostatin combined with radiotherapy.
Endostatin has been demonstrated to represent a promising novel medicine to treat malignant tumors, and it may be more effective when combined with conventional treatment. Meanwhile, a promising area of research in radiation oncology is the integration of molecular targeting agents to improve the effectiveness of radiotherapy (RT) in the control of primary tumor. Antiangiogenic agents are one such class of targeted therapies and have shown promise in both laboratory and clinical experiments. Endostatin in combination with RT has feasibility; but it also has lots of problems. Further understanding of the mechanisms is needed.
Zhuang
Hong-Qing
HQ
Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China.
Yuan
Zhi-Yong
ZY
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy; D043169:Endostatins / Q000235:genetics / Q000528:radiation effects / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000378:metabolism / Q000503:physiopathology; D005786:Gene Expression Regulation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins